News

Atrogi receives Eurostars grant to develop obesity project

Atrogi is one of a few companies to be selected for a prestigious grant from Eurostars, an initiative of the European Commission that promotes research, and the intergovernmental innovation network EUREKA. The application was done in consortium with Stockholm University, Maastricht University, the Latvian Institute of Organic Synthesis and Excellerate Bioscience. The grant awarded is …

Atrogi receives Eurostars grant to develop obesity project Read More »

Atrogi får Eurostars-anslag för utveckling av fetma-projekt

Atrogi har som en av få aktörer beviljats ett prestigefullt anslag från Eurostars, ett forskningsfrämjande initiativ av Europeiska kommissionen och det mellanstatliga innovationsnätverket EUREKA. Ansökan gjordes i konsortium med Stockholms universitet, Maastricht University, Latvian Institute of Organic Synthesis och Excellerate Bioscience. Anslaget på strax under 1 miljon euro sträcker sig över tre år. – Vi …

Atrogi får Eurostars-anslag för utveckling av fetma-projekt Read More »

Diabetes company Atrogi has completed a SEK 90 million rights issue for the continued in-house development of a new class of diabetes drug

The Swedish diabetes company Atrogi has recently completed a rights issue, raising approximately SEK 90 million. Among the anchor investors is South Korea’s largest venture capital company Korea Investment Partners (KIP). “We see the investment by such a strong and experienced player as KIP as powerful confirmation of our groundbreaking research and the market potential …

Diabetes company Atrogi has completed a SEK 90 million rights issue for the continued in-house development of a new class of diabetes drug Read More »

Diabetesbolaget Atrogi har genomfört en nyemission om 90 miljoner kronor för den fortsatta utvecklingen av en ny klass egenutvecklat diabetesläkemedel

Det svenska diabetesbolaget Atrogi har nyligen genomfört en nyemission och tillförts cirka 90 miljoner svenska kronor. Bland ankarinvesterarna märks Koreas största riskkapitalbolag, Korea Investment Partners (KIP). – Att en så stark och erfaren aktör som KIP satsar på Atrogi ser vi som ett starkt bevis på vår banbrytande forskning och marknadspotentialen för det läkemedel vi …

Diabetesbolaget Atrogi har genomfört en nyemission om 90 miljoner kronor för den fortsatta utvecklingen av en ny klass egenutvecklat diabetesläkemedel Read More »

BIO-Europe 2017 in Berlin

Atrogi participated in BIO-Europe 2017 in Berlin, which is the largest partnering meeting in Europe. The purpose was to present our type 2 diabetes project to pharmaceutical companies. At the meeting Atrogi met with several of the largest companies that are working in the diabetes area. The response was overwhelming and Atrogi will follow up the requests for information.

Swelife

5MSEK fund granted

This very prestigeful grant from the SWElifes accelerator program was received in fierce competition with other applicants.

Second patent granted

One of Atrogis patent application was granted in the US (US 9,784,726).